What is the recommended dose of Akynzeo (netupitant 300 mg + palonosetron 0.5 mg) for preventing post‑chemotherapy nausea and vomiting?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Akynzeo Dosing for Chemotherapy-Induced Nausea and Vomiting

The recommended dose of Akynzeo is one capsule containing 300 mg netupitant plus 0.5 mg palonosetron, taken orally 1 hour before chemotherapy on day 1 only, combined with dexamethasone. 1

Specific Dosing by Chemotherapy Type

Highly Emetogenic Chemotherapy (Including Cisplatin)

Akynzeo capsules:

  • Day 1: One capsule (300 mg netupitant/0.5 mg palonosetron) taken 1 hour before chemotherapy
  • Dexamethasone: 12 mg on day 1 (30 minutes before chemotherapy), then 8 mg once daily on days 2-4 1, 2

This regimen is supported by the 2020 ASCO guidelines, which specifically list netupitant-palonosetron 300 mg/0.5 mg as a category 1 recommendation for highly emetogenic chemotherapy 2. The combination demonstrated superior efficacy compared to palonosetron alone, with complete response rates of 89.6% versus 76.5% in the overall phase (0-120 hours) 3.

Moderately Emetogenic Chemotherapy (Including Anthracycline-Cyclophosphamide)

Akynzeo capsules:

  • Day 1: One capsule (300 mg netupitant/0.5 mg palonosetron) taken 1 hour before chemotherapy
  • Dexamethasone: 12 mg on day 1 (30 minutes before chemotherapy)
  • Days 2-3: No additional antiemetic treatment required 1

The pivotal trial in 1,455 patients receiving anthracycline-cyclophosphamide chemotherapy showed Akynzeo achieved 74.3% complete response versus 66.6% with palonosetron alone during the overall phase 4.

Important Administration Details

  • Can be taken with or without food 1
  • Single-dose administration on day 1 only - the long half-life of netupitant (90 hours) provides coverage through the delayed phase without repeat dosing 5
  • Do not administer more frequently than once per chemotherapy cycle 1

Intravenous Formulation Alternative

For patients unable to swallow capsules, Akynzeo is available as an intravenous formulation:

  • Fosnetupitant 235 mg/palonosetron 0.25 mg IV infused over 30 minutes, starting 30 minutes before chemotherapy 2, 1
  • Same dexamethasone dosing as oral formulation

Key Clinical Considerations

The combination of netupitant and palonosetron in a single capsule offers several advantages:

  • Dual-mechanism antiemetic coverage (NK1 and 5-HT3 receptor antagonism) in one dose
  • Simplified regimen improves guideline adherence compared to multi-drug protocols
  • Palonosetron's unique 40-hour half-life and higher receptor binding affinity provides superior delayed-phase protection compared to first-generation 5-HT3 antagonists 6

Critical pitfall to avoid: Do not reduce the dexamethasone dose to 8 mg on day 1 when using Akynzeo - the FDA-approved regimen specifies 12 mg dexamethasone (lower than the 20 mg used with palonosetron alone) because netupitant inhibits CYP3A4, increasing dexamethasone exposure 1.

The evidence consistently demonstrates that this single-capsule approach maintains efficacy across multiple chemotherapy cycles, with real-world data showing complete response rates of 97.5% in the acute phase and 95.09% in the delayed phase 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.